HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prestige Consumer Not Thirsty For Bringing International Sales Leader Hydralyte To US

Executive Summary

Expanding Hydralyte sales to US sports beverage market might seem a likely target for PCH. But firm doesn’t plan to bring its Hydralyte products to the US, where a smaller company owns and markets the brand.

You may also be interested in...



US Q2 Consumer Health Earnings Preview: Two Firsts On Table For Perrigo, One For Kenvue

Perrigo will note regulatory approval for Opill as first US OTC oral contraceptive in first earnings briefing with Patrick Lockwood-Taylor at helm. Other firsts in sector will be Kenvue’s 20 July results being its first since spin-out from J&J in May and Bausch + Lomb’s first quarterly results under CEO Saunders.

Prestige Consumer Stays In Motion In Goody’s Ad Campaign, Gets Moving In Dramamine Sweepstakes

“Get To Good” campaign features “characters who embody the Goody’s consumer, leading active lives and refusing to be slowed down by pain,” while Dramamine’s “Ditch the Drama Sweepstakes” offers “dream vacation anywhere in the world” and introduces “Drama Llama” as “spokescharacter.”  

Deal For TheraTears Emphasizes Prestige Is A Consumer Health Business, Akorn Isn't

Both firms announce agreement for Prestige to pay Akorn $230m cash for TheraTear, Diabetic Tussin and Zostrix OTCs and MagOx and Multi-betic supplements. Akorn says the agreement is "to sell its Consumer Health business,” even though it retains two consumer brands.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153641

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel